nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—ABCB1—esophageal cancer	0.72	1	CbGaD
Ergotamine—Dihydroergotamine—ABCB1—esophageal cancer	0.00171	0.415	CrCbGaD
Ergotamine—Ergonovine—ABCB1—esophageal cancer	0.00157	0.379	CrCbGaD
Ergotamine—Bromocriptine—ABCB1—esophageal cancer	0.00085	0.206	CrCbGaD
Ergotamine—CYP3A4—Metabolism—TYMP—esophageal cancer	3.3e-05	0.000119	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	3.27e-05	0.000118	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—EGFR—esophageal cancer	3.27e-05	0.000118	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HIF1A—esophageal cancer	3.21e-05	0.000116	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.21e-05	0.000116	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	3.2e-05	0.000116	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—NOTCH1—esophageal cancer	3.2e-05	0.000116	CbGpPWpGaD
Ergotamine—HTR1D—GPCR downstream signaling—PIK3CA—esophageal cancer	3.19e-05	0.000115	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—MYC—esophageal cancer	3.15e-05	0.000114	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ALDH2—esophageal cancer	3.15e-05	0.000114	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	3.14e-05	0.000114	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.12e-05	0.000113	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CREBBP—esophageal cancer	3.12e-05	0.000113	CbGpPWpGaD
Ergotamine—HTR1B—GPCR downstream signaling—PIK3CA—esophageal cancer	3.12e-05	0.000113	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	3.1e-05	0.000112	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	3.08e-05	0.000112	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—EGFR—esophageal cancer	3.08e-05	0.000111	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—KDR—esophageal cancer	3.07e-05	0.000111	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—EGFR—esophageal cancer	3.07e-05	0.000111	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—NOS3—esophageal cancer	3.04e-05	0.00011	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GSTT1—esophageal cancer	3e-05	0.000108	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.99e-05	0.000108	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TPI1—esophageal cancer	2.98e-05	0.000108	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.98e-05	0.000108	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	2.98e-05	0.000108	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—NOS3—esophageal cancer	2.98e-05	0.000108	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—MYC—esophageal cancer	2.97e-05	0.000107	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—KDR—esophageal cancer	2.96e-05	0.000107	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	2.96e-05	0.000107	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	2.96e-05	0.000107	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HIF1A—esophageal cancer	2.95e-05	0.000107	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.95e-05	0.000107	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—KDR—esophageal cancer	2.95e-05	0.000107	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.93e-05	0.000106	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—EGFR—esophageal cancer	2.91e-05	0.000105	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CREBBP—esophageal cancer	2.9e-05	0.000105	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—PIK3CA—esophageal cancer	2.89e-05	0.000105	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NOTCH1—esophageal cancer	2.89e-05	0.000105	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—TP53—esophageal cancer	2.86e-05	0.000103	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.86e-05	0.000103	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—EGFR—esophageal cancer	2.85e-05	0.000103	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	2.84e-05	0.000103	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	2.83e-05	0.000103	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—KDR—esophageal cancer	2.82e-05	0.000102	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.81e-05	0.000102	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS1—esophageal cancer	2.81e-05	0.000102	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ENO1—esophageal cancer	2.81e-05	0.000102	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—NOS3—esophageal cancer	2.79e-05	0.000101	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	2.79e-05	0.000101	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	2.78e-05	0.000101	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	2.78e-05	0.0001	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PSME1—esophageal cancer	2.77e-05	0.0001	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PSME2—esophageal cancer	2.77e-05	0.0001	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.75e-05	9.95e-05	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—PIK3CA—esophageal cancer	2.73e-05	9.87e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.73e-05	9.86e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HIF1A—esophageal cancer	2.72e-05	9.84e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	2.68e-05	9.68e-05	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—PIK3CA—esophageal cancer	2.67e-05	9.67e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	2.66e-05	9.63e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	2.66e-05	9.62e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CREBBP—esophageal cancer	2.62e-05	9.49e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	2.62e-05	9.48e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	2.61e-05	9.46e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—KDR—esophageal cancer	2.6e-05	9.41e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—NOS3—esophageal cancer	2.6e-05	9.41e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GNG7—esophageal cancer	2.59e-05	9.38e-05	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—TP53—esophageal cancer	2.59e-05	9.36e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—EGFR—esophageal cancer	2.58e-05	9.32e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—HMOX1—esophageal cancer	2.56e-05	9.28e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—KDR—esophageal cancer	2.56e-05	9.26e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	2.53e-05	9.16e-05	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—PIK3CA—esophageal cancer	2.52e-05	9.12e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	2.52e-05	9.11e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CCND1—esophageal cancer	2.51e-05	9.08e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—KDR—esophageal cancer	2.51e-05	9.07e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	2.49e-05	9e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—PIK3CA—esophageal cancer	2.48e-05	8.96e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	2.47e-05	8.95e-05	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.46e-05	8.91e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CCND1—esophageal cancer	2.46e-05	8.89e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	2.45e-05	8.87e-05	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—TP53—esophageal cancer	2.44e-05	8.83e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	2.44e-05	8.81e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—ERBB2—esophageal cancer	2.43e-05	8.8e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.43e-05	8.79e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	2.43e-05	8.79e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.42e-05	8.74e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	2.41e-05	8.73e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	2.41e-05	8.72e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	2.39e-05	8.63e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—CREBBP—esophageal cancer	2.38e-05	8.61e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	2.38e-05	8.6e-05	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.38e-05	8.6e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	2.37e-05	8.57e-05	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	2.36e-05	8.56e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	2.36e-05	8.54e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	2.35e-05	8.49e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—KDR—esophageal cancer	2.33e-05	8.43e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.31e-05	8.36e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—EP300—esophageal cancer	2.31e-05	8.36e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CCND1—esophageal cancer	2.31e-05	8.35e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.28e-05	8.27e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NOS3—esophageal cancer	2.27e-05	8.2e-05	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.26e-05	8.19e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—EP300—esophageal cancer	2.26e-05	8.19e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	2.25e-05	8.16e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	2.24e-05	8.12e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	2.24e-05	8.09e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	2.23e-05	8.08e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CREBBP—esophageal cancer	2.22e-05	8.04e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	2.2e-05	7.94e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	2.19e-05	7.94e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	2.19e-05	7.91e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—EGFR—esophageal cancer	2.18e-05	7.9e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ENO1—esophageal cancer	2.17e-05	7.84e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.17e-05	7.84e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	2.16e-05	7.81e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	2.16e-05	7.81e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CCND1—esophageal cancer	2.15e-05	7.77e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	2.15e-05	7.77e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	2.15e-05	7.77e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	2.14e-05	7.75e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PSME2—esophageal cancer	2.13e-05	7.72e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PSME1—esophageal cancer	2.13e-05	7.72e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—NOS3—esophageal cancer	2.13e-05	7.71e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EP300—esophageal cancer	2.13e-05	7.69e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	2.12e-05	7.67e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	2.11e-05	7.63e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	2.1e-05	7.61e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	2.09e-05	7.55e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CDKN1A—esophageal cancer	2.08e-05	7.52e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	2.06e-05	7.44e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.05e-05	7.43e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—HMOX1—esophageal cancer	2.05e-05	7.41e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	2.02e-05	7.3e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—MYC—esophageal cancer	2.01e-05	7.29e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.01e-05	7.27e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.01e-05	7.27e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NOS3—esophageal cancer	1.99e-05	7.2e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	1.99e-05	7.2e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EP300—esophageal cancer	1.98e-05	7.16e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—MYC—esophageal cancer	1.97e-05	7.13e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—EGFR—esophageal cancer	1.97e-05	7.13e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.97e-05	7.11e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	1.96e-05	7.08e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	1.95e-05	7.07e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTGS2—esophageal cancer	1.95e-05	7.05e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	1.94e-05	7.02e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—EGFR—esophageal cancer	1.93e-05	6.98e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	1.92e-05	6.94e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	1.9e-05	6.86e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	1.88e-05	6.79e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CCND1—esophageal cancer	1.87e-05	6.78e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.87e-05	6.76e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.86e-05	6.75e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	1.86e-05	6.74e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—ERBB2—esophageal cancer	1.86e-05	6.73e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MYC—esophageal cancer	1.85e-05	6.7e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.84e-05	6.66e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	1.83e-05	6.63e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.83e-05	6.61e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EGFR—esophageal cancer	1.81e-05	6.55e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	1.81e-05	6.55e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	1.8e-05	6.52e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	1.79e-05	6.49e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EP300—esophageal cancer	1.79e-05	6.46e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	1.78e-05	6.45e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	1.78e-05	6.44e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.73e-05	6.26e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	1.73e-05	6.24e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EP300—esophageal cancer	1.72e-05	6.24e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MYC—esophageal cancer	1.72e-05	6.24e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EP300—esophageal cancer	1.72e-05	6.2e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	1.71e-05	6.18e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.7e-05	6.14e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EGFR—esophageal cancer	1.69e-05	6.1e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	1.67e-05	6.06e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	1.67e-05	6.03e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—esophageal cancer	1.65e-05	5.98e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CREBBP—esophageal cancer	1.65e-05	5.95e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCND1—esophageal cancer	1.64e-05	5.95e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EP300—esophageal cancer	1.64e-05	5.94e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—EP300—esophageal cancer	1.62e-05	5.86e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—esophageal cancer	1.62e-05	5.86e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	1.62e-05	5.85e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	1.59e-05	5.75e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	1.58e-05	5.73e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.58e-05	5.72e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	1.57e-05	5.69e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	1.57e-05	5.66e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MYC—esophageal cancer	1.56e-05	5.63e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	1.53e-05	5.54e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	1.52e-05	5.51e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—esophageal cancer	1.52e-05	5.5e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.52e-05	5.49e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EP300—esophageal cancer	1.51e-05	5.48e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MYC—esophageal cancer	1.5e-05	5.43e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MYC—esophageal cancer	1.49e-05	5.41e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EP300—esophageal cancer	1.49e-05	5.39e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.49e-05	5.38e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—NOS3—esophageal cancer	1.47e-05	5.33e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	1.47e-05	5.33e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EGFR—esophageal cancer	1.47e-05	5.32e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PIK3CA—esophageal cancer	1.46e-05	5.29e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	1.46e-05	5.29e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EP300—esophageal cancer	1.46e-05	5.28e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MYC—esophageal cancer	1.43e-05	5.18e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	1.42e-05	5.15e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—esophageal cancer	1.42e-05	5.12e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	1.4e-05	5.06e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EP300—esophageal cancer	1.35e-05	4.9e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—esophageal cancer	1.35e-05	4.87e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	1.32e-05	4.78e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MYC—esophageal cancer	1.32e-05	4.77e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CREBBP—esophageal cancer	1.31e-05	4.75e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MYC—esophageal cancer	1.3e-05	4.69e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EGFR—esophageal cancer	1.29e-05	4.67e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—esophageal cancer	1.28e-05	4.62e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	1.28e-05	4.61e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MYC—esophageal cancer	1.27e-05	4.6e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	1.27e-05	4.59e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	1.27e-05	4.59e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	1.24e-05	4.5e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—esophageal cancer	1.23e-05	4.46e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—esophageal cancer	1.23e-05	4.44e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	1.21e-05	4.39e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PIK3CA—esophageal cancer	1.2e-05	4.34e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MYC—esophageal cancer	1.18e-05	4.27e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—NOS3—esophageal cancer	1.18e-05	4.25e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—esophageal cancer	1.17e-05	4.25e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	1.15e-05	4.18e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—EP300—esophageal cancer	1.12e-05	4.05e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	1.12e-05	4.05e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	1.1e-05	3.99e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—esophageal cancer	1.08e-05	3.92e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	1.08e-05	3.9e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—esophageal cancer	1.08e-05	3.89e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—esophageal cancer	1.07e-05	3.86e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—esophageal cancer	1.04e-05	3.78e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.01e-05	3.67e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	1e-05	3.63e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—esophageal cancer	9.7e-06	3.51e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NOS3—esophageal cancer	9.08e-06	3.28e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—EP300—esophageal cancer	8.95e-06	3.24e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—esophageal cancer	8.3e-06	3e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CA—esophageal cancer	8.29e-06	3e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—EP300—esophageal cancer	6.9e-06	2.5e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	6.62e-06	2.39e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	5.11e-06	1.85e-05	CbGpPWpGaD
